No Data
Cardiol Therapeutics Analyst Ratings
Cardiol Therapeutics' CardiolRx Gains Buy Rating on Positive Phase 2 Results and Strong Financial Position
CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study
Cardiol Therapeutics' Presents Phase II MAvERIC-Pilot Clinical Results In Recurrent Pericarditis Presented At The AHA Scientific Sessions 2024; Marked And Rapid Reductions In Both Pericarditis Pain And Inflammation Maintained Throughout The 26-Week Study
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
US Manufacturing Index Rises To 43, Highest Since 2020
No Data
No Data
